Adults 60 to 85, any sex, with Hearing Loss, Sensorineural or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Cognitive Screening Results (Montreal Cognitive Assessment)Primary· The outcome measure was assessed immediately after the test. This applies to both conditions for all the arms.
The cognitive screening test of Montreal Cognitive Assessment (MoCA) was administered to 4 groups with different administration method conditions (see arms/groups table).
MoCA is s standardized cognitive screening tool for mild cognitive impairment and dementia. The total score was used as outcome measure of this study and this score ranges from 0-30, with higher score being better performance.
Auditory Working Memory PerformanceSecondary· The outcome measure will be assessed immediately after the test.
Older individuals were presented with lists of words and instructed to repeat them back. After each word list, they had to recall the words.
Condition 1
Group
Value
95% CI
Group1: Younger Control (Auditory Unamplified - Visual)
82.88
± 6.7
Group2: Auditory Amplified - Visual
72.3
± 7.1
Group3: Auditory Amplified - Unamplified
69.1
± 8.2
Group4: Auditory Unamplified - Visual
57.5
± 11.5
Condition 2
Group
Value
95% CI
Group1: Younger Control (Auditory Unamplified - Visual)
82.11
± 7.6
Group2: Auditory Amplified - Visual
66.9
± 9.66
Group3: Auditory Amplified - Unamplified
64.5
± 11.4
Group4: Auditory Unamplified - Visual
61.3
± 14.5
Sponsor's own description
The objectives of the current project aim to determine whether a more controlled amplification method or a visual administration has an effect on hearing impaired older individuals' cognitive test scores.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Other recruiting trials for Hearing Loss, Sensorineural
Currently open trials in the same condition.
NCT06499805 — Barriers and Facilitators to OTC Hearing Aids Success
· NA
· recruiting
NCT06560918 — Self-efficacy-based Auditory Rehabilitation With Over-the-Counter Hearing Aids
· NA
· recruiting
NCT06882889 — Comparing the Efficacy of Domestic Versus Imported Hearing Aids in ARHL
· NA
· recruiting
NCT06664697 — Post-Market Clinical Investigation of the IotaSOFT Insertion System
· recruiting
NCT06268340 — Hearing and Structure Preservation Via ECochG
· NA
· recruiting
Other Northwestern University trials
Trials by the same sponsor.
NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies
· Phase 1, PHASE2
· not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C
· EARLY_PHASE1
· not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community
· NA
· not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill
· NA
· not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 3 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03402932.